AOD-9604 and Clopidogrel Interaction: What Patients and Clinicians Need to Know

What Is AOD-9604 and Why Does It Matter for Drug Interactions?

AOD-9604 is a 16-amino-acid synthetic peptide derived from the C-terminal end of human growth hormone (residues 176 to 191). Researchers originally investigated it for lipolytic activity and adipose tissue modulation. In clinical practice today, it appears most often in 503A compounding pharmacy formulations prescribed off-label for body composition goals.

Because AOD-9604 is a peptide and not a small molecule, its metabolic fate differs substantially from most drugs in the interaction databases. It does not carry a standard FDA New Drug Application, which means no sponsor-submitted interaction studies exist in the FDA's public records. Clinicians and patients therefore have to reason from first principles when asking whether combining it with an established pharmaceutical like clopidogrel is safe.

How AOD-9604 Is Metabolized

Peptides of this size are broken down primarily by circulating and tissue-bound proteases, not by hepatic cytochrome P450 (CYP) enzymes. This is a key pharmacokinetic fact. The standard CYP450 interaction framework that governs most small-molecule DDI risk simply does not apply the same way to a 16-residue peptide.

Subcutaneous injection, the most common administration route, allows the peptide to enter systemic circulation, where proteolytic degradation produces individual amino acids that re-enter the normal amino acid pool. No metabolite of AOD-9604 has been identified in published literature as a CYP inhibitor or inducer.

Why Clopidogrel's Metabolism Demands Careful Thought

Clopidogrel is a prodrug. Roughly 85% of an absorbed dose is hydrolyzed by esterases to an inactive carboxylic acid derivative before it ever reaches CYP enzymes. The remaining 15% undergoes two sequential CYP-mediated oxidation steps, with CYP2C19 driving the rate-limiting second step that generates the active thiol metabolite responsible for irreversible P2Y12 receptor blockade on platelets [1].

The FDA label for clopidogrel (NDA 020839) explicitly warns that CYP2C19 inhibitors, particularly omeprazole and esomeprazole, reduce active metabolite exposure and may reduce clinical efficacy [2]. This is the mechanism that drives most clopidogrel DDI concern. Because AOD-9604 does not appear to be a CYP2C19 substrate or inhibitor based on its peptide structure and known protease-based clearance, the classical pharmacokinetic interaction pathway is not triggered.

Pharmacokinetic Interaction Risk: CYP2C19, CYP3A4, and P-Glycoprotein

The three most clinically relevant pharmacokinetic pathways for clopidogrel are CYP2C19 (rate-limiting activation step), CYP3A4 (minor activation pathway), and P-glycoprotein (intestinal efflux transporter affecting absorption of certain co-medications).

CYP2C19 Pathway

AOD-9604 has no identified substrate, inhibitory, or inductive activity at CYP2C19 in any published in-vitro or in-vivo study. Peptides of this molecular weight are not efficiently taken up by hepatocytes in quantities sufficient to modulate CYP enzyme expression. The absence of evidence is not proof of safety, but the mechanistic argument against a CYP2C19 interaction is strong.

For reference, CYP2C19 poor metabolizers, who carry loss-of-function alleles (CYP2C19*2 or *3), show a 32 to 40% reduction in active clopidogrel metabolite exposure compared to extensive metabolizers [3]. That magnitude of effect from a genetic variant gives clinicians a useful scale: a compound would need to produce substantial enzyme inhibition to meaningfully suppress clopidogrel activation.

CYP3A4 and Intestinal P-Glycoprotein

CYP3A4 contributes to the first oxidation step in clopidogrel bioactivation. Again, peptide metabolism does not rely on CYP3A4, and no in-vitro assay has identified AOD-9604 as a ligand for this enzyme. P-glycoprotein is primarily a concern for orally administered clopidogrel tablets (the brand Plavix and its generics). AOD-9604 is injected subcutaneously, so any intestinal P-gp competition is irrelevant by route of administration.

What the DDI Databases Say

Standard interaction databases (Lexicomp, Micromedex, Drugs.com, Clinical Pharmacology) do not list any interaction between AOD-9604 and clopidogrel. This reflects the absence of published evidence rather than a confirmed clear-drug interaction signal. Clinicians should interpret the "no interaction listed" status as meaning "not studied" rather than "confirmed safe."

Pharmacodynamic Interaction Risk: Bleeding and Platelet Function

This is the more clinically relevant concern for most patients. Even if two drugs do not interact pharmacokinetically, they can interact pharmacodynamically if both affect the same physiological process.

Clopidogrel produces irreversible inhibition of the P2Y12 ADP receptor, measurably reducing platelet aggregation within 2 hours of a 300 to 600 mg loading dose and achieving steady-state inhibition after 3 to 7 days of 75 mg once-daily maintenance dosing [2].

Does AOD-9604 Affect Platelet Function?

This is where the evidence gap becomes most significant. No published human study has measured platelet aggregation, bleeding time, or thromboelastography parameters in subjects receiving AOD-9604. Preclinical data from the original Australian research program (Monash University, Metabolic Pharmaceuticals) focused primarily on adiposity endpoints in diet-induced obese mice and in a Phase IIb trial (METAOD006, N=300) that examined body weight, not hemostasis [4].

Growth hormone itself can influence platelet function through IGF-1-mediated pathways, but AOD-9604 was specifically designed to dissociate from GH receptor binding. Clinical studies, including METAOD004 and METAOD006, confirmed that AOD-9604 at doses up to 1 mg/day did not raise IGF-1 above baseline levels [4]. The absence of IGF-1 elevation makes growth-hormone-class platelet effects less plausible, though not impossible.

A Clinical Risk-Stratification Framework for Co-Administration

Given the evidence vacuum, the following three-tier framework may help prescribers decide how to counsel patients already on clopidogrel who ask about AOD-9604:

Tier 1: Lowest concern. Patient is on clopidogrel for stable coronary artery disease, has no prior bleeding events, takes no other antiplatelet or anticoagulant agents, and plans AOD-9604 at standard compounded doses (typically 250 to 500 mcg subcutaneously once daily). Proceed with counseling on bleeding warning signs. No dose adjustment of clopidogrel is mechanistically justified.

Tier 2: Moderate concern. Patient is on dual antiplatelet therapy (clopidogrel plus aspirin) or concurrently uses an NSAID, omega-3 fatty acids at high doses, or other compounds with possible antiplatelet properties. In this setting, any additive pharmacodynamic bleeding risk from AOD-9604, even if small, is stacked on top of an already-elevated baseline risk. Platelet function testing before initiating AOD-9604 is reasonable.

Tier 3: Highest concern. Patient is post-drug-eluting stent within 12 months, has active GI ulcer disease, or has a history of intracranial hemorrhage. Clopidogrel cannot be safely discontinued in this context, and the absence of human safety data for AOD-9604 as an add-on to aggressive antiplatelet regimens warrants deferring AOD-9604 use entirely until further evidence is available.

Regulatory and Compounding Context

Clopidogrel (Plavix) received FDA approval in 1997 and has a fully characterized prescribing information document updated through 2024 [2]. Dosing is 75 mg orally once daily for most indications, with a 300 mg loading dose used in acute coronary syndromes.

AOD-9604 occupies a different regulatory space entirely. The FDA has not approved it as a drug product. It is available through 503A compounding pharmacies, which operate under state pharmacy board oversight and fill prescriptions for individual patients from licensed prescribers. The FDA placed AOD-9604 on its list of bulk drug substances that may be used in 503A compounding under interim policy, but the agency has not evaluated it through the standard NDA process, meaning no clinical pharmacology studies, including drug interaction studies, have been formally submitted or reviewed [5].

This regulatory distinction matters clinically. When a patient asks "can I take AOD-9604 with clopidogrel," they are asking about a combination for which no regulatory authority has reviewed interaction data.

What Prescribers of Compounded AOD-9604 Must Disclose

A prescriber issuing a compounded AOD-9604 prescription should document in the chart that the patient is on clopidogrel, that no published human DDI data exists, and that the risk assessment is based on mechanistic reasoning. This protects both the patient and the prescriber. The FDA's guidance on 503A compounding does not require interaction studies before dispensing, but standard medical practice obligates the prescriber to exercise reasonable clinical judgment [5].

Monitoring Recommendations for Patients Taking Both Agents

Because no human DDI data exists, monitoring serves as the primary safety strategy when a clinician determines that co-administration is appropriate.

Platelet Function Testing

Platelet function assays are available and clinically validated. The VerifyNow P2Y12 assay measures clopidogrel's antiplatelet effect directly and reports results as P2Y12 Reaction Units (PRU). A PRU above 208 is associated with high on-treatment platelet reactivity and increased ischemic risk [6]. A PRU below 85 is associated with increased bleeding risk.

Obtaining a baseline PRU before initiating AOD-9604, and repeating it 4 weeks after starting, gives the clinician an objective measure of whether platelet inhibition has changed. If PRU falls unexpectedly after adding AOD-9604, pharmacodynamic interaction becomes more plausible and warrants dose reconsideration.

Clinical Bleeding Surveillance

Patients should be counseled to report any of the following within 48 hours of onset:

• Gum bleeding that does not stop within 10 minutes of local pressure
• Unexplained bruising larger than a palm
• Blood in urine or stool
• Prolonged bleeding from minor cuts (more than 15 minutes)
• Sudden severe headache or vision changes (symptoms of intracranial hemorrhage)

These thresholds are adapted from the ISTH bleeding assessment tool, which has been validated for antiplatelet-related bleeding surveillance in outpatient populations [7].

CYP2C19 Genotyping

The AHA and ACC recommend CYP2C19 genotyping to guide antiplatelet therapy in patients with acute coronary syndrome or following PCI [8]. If a patient has not yet been genotyped, adding any new compound (including AOD-9604) is a reasonable trigger to perform this test. Poor metabolizers (CYP2C19*2/*2 homozygotes) have substantially reduced clopidogrel efficacy regardless of any peptide co-administration, and prasugrel or ticagrelor may be superior alternatives in that setting.

Patient Counseling Points

Patients searching for information about combining AOD-9604 with clopidogrel often encounter marketing content that either dismisses all interaction concerns or catastrophizes them. Neither extreme is accurate.

The evidence-based counseling message is this: no published human data confirms either a harmful interaction or a safe combination. The pharmacokinetic case for a CYP2C19-mediated interaction is weak based on what is known about peptide metabolism. The pharmacodynamic case for additive bleeding risk is plausible but unproven. You should tell your cardiologist or prescribing physician about every compounded peptide you take, without exception.

The American Heart Association's 2023 dual antiplatelet therapy guidance states: "Clinicians should elicit a complete medication history that includes nonprescription, herbal, and compounded preparations, because any agent with potential antiplatelet or anticoagulant properties warrants careful risk-benefit evaluation in patients on P2Y12 inhibitor therapy" [8].

Patients should also understand that AOD-9604 is not a controlled substance and not a scheduled drug, but the absence of federal scheduling does not imply the FDA has cleared it for human use alongside other medications. Compounded peptides exist outside the standard pharmacovigilance infrastructure, so adverse event reporting is inconsistent.

Summary of the Evidence and Clinical Bottom Line

The available evidence can be summarized in three direct statements.

First, no published pharmacokinetic interaction study exists for AOD-9604 combined with clopidogrel in humans or in validated in-vitro CYP assay systems.

Second, the mechanistic case for a CYP2C19 or CYP3A4-mediated pharmacokinetic interaction is weak, because AOD-9604 is a peptide cleared by proteolysis rather than hepatic oxidative metabolism.

Third, a pharmacodynamic interaction cannot be excluded because no human platelet function data exists for AOD-9604, and the effect of this peptide on hemostasis has not been measured in any published clinical trial.

The METAOD006 trial enrolled 300 participants over 24 weeks and detected no serious adverse cardiovascular or hematologic events in the AOD-9604 arms, but the trial was not powered or designed to detect drug interactions with antiplatelet agents [4]. That single datum is the closest the literature comes to human safety reassurance, and it is distant from the specific question of coadministration with clopidogrel.

Clinicians operating in the 503A compounding space should apply the same standard of care they would apply to any combination of an investigational agent with a high-risk medication: document the rationale, obtain informed consent that includes the evidence gap, baseline platelet function if feasible, and follow up at 4 weeks with a targeted bleeding assessment. Patients on dual antiplatelet therapy or with recent coronary stenting should defer AOD-9604 until human DDI data becomes available.